Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than two months.

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and Company (NYSE:LLY) released updated results from Phase 3 EMBER-3 study of Inluriyo (imlunestrant),

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about jobs and timeline.

Notably, the Huntsville site will be among those that will manufacture orforglipron, Lilly’s first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year.

Eli Lilly and Company (NYSE: LLY) is one of the stocks Jim Cramer answered questions about. Inquiring if their portfolio is diversified, a caller highlighted that their top five holdings are LLY, SLG, MSFT, CVX, and TSM. Cramer said:

Healthcare giant Eli Lilly is now the first global healthcare company to hit $1 trillion in value riding on the popularity of Zepbound and Mounjaro.

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.

Lilly has already submitted the combination data for US regulatory review in ESR1-mutated metastatic breast cancer. Additionally, imlunestrant is being studied in the EMBER-4 trial, which has enrolled ~8,000 patients to investigate its potential in the adjuvant setting for early breast cancer.

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels. Eli Lilly's (NYSE: LLY) share price has soared over the past five years (up 530%).

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic knee pain after 68 weeks

Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity drug market as they race to secure dominance before lower-cost generic alternatives arrive in